To treat MASLD or MASH, silymarin impacts several targets including farnesoid X receptor, Nrf2, SIRT1, SIRT2, AMPK, and the NLRP3 inflammasome. Here, SIRT1 is linked to metabolic dysfunction-associated steatotic liver disease.